Axogen (AXGN) Q2 Revenue Jumps 18%

Axogen (NASDAQ:AXGN), a regenerative medicine company focused on surgical solutions for peripheral nerve injuries, reported results on August 5, 2025. The standout news in this earnings release was a clear beat on both GAAP revenue and non-GAAP earnings, with GAAP revenue coming in at $56.7 million compared to the $52.66 million estimate and Non-GAAP earnings per share (EPS) of $0.12, doubling analyst expectations of $0.06. Compared to Q2 2024, both GAAP revenue and profits (GAAP and non-GAAP) rose meaningfully, with broad growth from all core business areas. Management also raised full-year revenue growth guidance to at least 17% for 2025. The quarter reflected continuing commercial momentum, improved profitability, and further progress toward important regulatory milestones, especially the upcoming Biologics License Application (BLA) decision for the company’s lead product, Avance® Nerve Graft, which has a Prescription Drug User Fee Act goal date of September 5, 2025. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Axogen develops and markets specialized products to surgically repair and protect damaged peripheral nerves. Its product suite includes Avance Nerve Graft, a processed human nerve allograft used to bridge nerve gaps, and Axoguard Nerve Connector, a conduit made from processed porcine extracellular matrix (ECM) used to join severed nerves. Other key offerings include Axoguard Nerve Protector, HA+ Nerve Protector, Nerve Cap, and Avive+ Soft Tissue Matrix, each aimed at improving outcomes in nerve surgery by either regeneration or protection of nerve tissue.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool